| Detailed information |
|---|
| CancerLivER ID | 2593 |
| Biomarker | DNMBP, CD44, POSTN |
| Biomarker Name/Symbol (given in Publication) | DNMBP, CD44, and POSTN |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential progostic marker for Extrahepatic recurrence in HCC; but not validated on indpendent dataset |
| Experimental Condition | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC with EHR than HCC without EHR and non-cancerous liver tissue ( but similar expression in HCC without EHR and non-cancerous liver tissue) |
| Level of significance | P< 0.05 |
| Source | Tissue |
| PMID | 17016605 |
| Type of Biomarker | Prognostic |
| Pathway | Cell adhesion |
| Cohort | 76 HCC samples : 35 HCC for recurrence (5 had extrahepatic metastases at surgery, and 5 had EHR after curative surgery. These 10 patients were classified as the EHR group. The remaining 25 patients, who had no EHR during the follow-up period, were classified as the non-EHR group). |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |